You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Tango

COMPARATIVE STUDY OF DOVATO vs TAF-CONTAINING REGIMENS IN MORE THAN 700 VIROLOGICALLY SUPPRESSED PATIENTS

Phase III, Randomised, Multicentre, Parallel-Group, Non-Inferiority Switch Study 1
Comparative study

CONFIDENCE WITH POWERFUL EFFICACY MAINTAINED AT WEEK 48

No Increased Risk of Virological Failure vs TAF-Containing Regimens 1
Powerful efficacy maintained at Wk48

ITT–E Snapshot analysis.

Adapted from van Wyk et al, 2019. 1

REASSURANCE WITH A HIGH BARRIER TO RESISTANCE UP TO 48 WEEKS

Reassurance with a high barrier

§Patients met confirmed virological withdrawal criteria if they had 1 assessment with HIV-1 RNA ≥200 copies/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 copies/mL

References:

  1. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study). Presented at: International AIDS Conference; July 21-24, 2019; Mexico City. Slides WEAB0403LB.
  2. Dovato Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last Accessed, June 2020.

 

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.